TARGET RESEARCH ARTICLES
-
![Human lungs respiratory system-GettyImages-1334425398]( "Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?")
Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as a strategy in respiratory disease. This article highlights some promising drug candidates and next-generation approaches.
-
![Missing puzzle piece-GettyImages-185243756]( "The Missing Data Set In Drug Discovery: Patient Experience As Decision Data")
The Missing Data Set In Drug Discovery: Patient Experience As Decision DataDrug discovery has become highly effective at capturing molecular detail, yet the experience of disease remains difficult to incorporate into early scientific decisions.
-
![Human lung cancer under microscope-GettyImages-2207680068]( "What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment")
What's Next For ADCs: How Combinations Will Help Define The Future Of TreatmentInsights gained from advancing ADC combination therapies in lung cancer are now shaping innovative approaches across multiple tumor types.
-
![brain damage in Alzheimer’s disease-GettyImages-2236863702]( "Rethinking Tau Biology: The Future Of Neurodegenerative Drug Discovery")
Rethinking Tau Biology: The Future Of Neurodegenerative Drug DiscoveryWe caught up with Melissa Murray, Ph.D., and Amy Rommel, Ph.D., to discuss tau-associated neurodegenerative diseases.
-
![Human genomics research-GettyImages-2221127854]( "Proteomics Biomarkers Beyond Blood")
Proteomics Biomarkers Beyond BloodEffective biomarker strategies have the potential to accelerate decision-making, de-risk development, and help drive precision medicine.
-
![prostate-specific antigen PSA-GettyImages-2160461582]( "The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era")
The Advantages Of Antibodies Over Ligands In The Alpha Emitter EraThe alpha era in radiopharmaceuticals is still being defined. The choices developers make now about delivery platforms will shape individual programs and the trajectory of the field.
TARGET RESEARCH VIDEOS
Panelists debate whether NAMS can replace 10% of animal testing for regulatory submissions by 2030. Shashi asserts that big pharma is already reducing animal use, while Samantha cites the EU’s success in cosmetics and FDA’s roadmap for monoclonals. Zaher predicts over 50% replacement by 2030, citing OECD updates and liver injury data.
Zaher frames the urgency of NAMS adoption by highlighting the staggering 92% drug failure rate in clinical trials despite animal testing. He explains how interdisciplinary convergence and AI are accelerating the shift toward human-relevant models, positioning NAMS as a solution to systemic inefficiencies in drug development.
Collaboration across sites is critical in the journey from development to manufacturing. Watch to discover how to accelerate cross-site collaboration with simple assay transfer.
Hear from Dr. Fabio Luciani, Professor and Senior Researcher in Systems Immunology at the School of Medical Sciences and the Kirby Institute at UNSW Sydney about his recent research.
TARGET RESEARCH ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
![accuracy-in-drug-development-GettyImages-2249698250]( "Integrating High-Content Imaging With Traditional Plate-Based Screening")
Gain mechanistic insights beyond traditional viability assays, revealing nuanced cellular phenotypes and strengthening early drug discovery decisions without sacrificing throughput or efficiency.
-
![GettyImages-1182436133 scientist, lab, research, oncology]( "Accelerating Discovery Success With Structure-Guided Drug Design")
Structure‑enabled drug discovery revealed a novel, druggable binding site in Artemis, enabling rapid SAR optimization and a ~500‑fold potency improvement against a challenging oncology target.
-
![antibody molecules-GettyImages-2165626333]( "ADC Development Grows More Complex — SPR Insights Bring Clarity")
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
![GettyImages-2181934436-laboratory-analysis-scientists-technology-computer]( "Translating Massive Data Into Therapeutic Momentum")
New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.
-
![Pipetting Samples Into Well Plate GettyImages-532258611]( "Residual iPSC And Genomic Stability Testing With High Multiplex Digital PCR")
Sensitive digital PCR methods enable confident detection of low‑abundance iPSC markers. Gain insight into how these capabilities support more reliable monitoring and quality assessment.
-
![GettyImages-2166558808-data-gene-dna-genomic]( "Everything You Need To Know About NGS")
Next generation sequencing technologies and workflow automation are accelerating genomic research. Learn key differences between sequencing methods and uncover strategies to boost efficiency.
TARGET RESEARCH SOLUTIONS
-
![VIAFLO 384]( "Efficient High Throughput scNMT Profiling")
High‑throughput scNMT‑seq offers a powerful way to map methylation and transcriptional activity. Learn about strategies that cut variability and support dependable multi‑omics datasets.
-
![Organ-On-A-Chip]( "An Organ-Chip Platform That Generates Human-Relevant Data At Scale")
Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.
-
![Emulate - Organ On A Chip Intro]( "A Revolutionary Consumable Empowering High-Throughput Organ-Chip Studies")
With 12 independent Emulations in one consumable, Chip-Array optimizes workflows and reduces cell requirements—delivering scalable, physiologically relevant models for advanced research.
-
![Chip-S1]( "Complete Organ-Chip Solutions To Fast-Track Your Drug Discovery")
From cancer models to high-throughput screening, Organ-Chip platforms accelerate development, improve safety, and support regulatory compliance for next-generation therapies.
-
![GettyImages-1648451466-scientist-cell-culture-laboratory-pipette-research]( "Immunoassays For Cytokine And Chemokine Quantitation")
Achieve precise cytokine and chemokine quantitation with flexible immunoassay solutions, including multiplexed bead-based assays, ELISA kits, and ELISPOT reagents, for human, rat, and mouse studies.
-
![GettyImages-1475620245 lab, assay]( "On-Target And Off-Target Assessment Assays")
Our comprehensive off-target gene editing assessment platform integrates screening, nomination, and confirmation assays, providing unmatched precision in guide RNA selection and off-target risk assessment. By addressing safety and regulatory expectations early, our platform reduces development risks, streamlines therapeutic design, and accelerates your path to the clinic with confidence and efficiency.
